Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study

Basit Öğe Kaydı
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorMermer, Sinan
dc.contributor.authorDemirdal, Tuna
dc.contributor.authorUlu, Ashhan Candevir
dc.contributor.authorFillatre, Pierre
dc.contributor.authorOzcem, Selin Bardak
dc.contributor.authorKaya, Safak
dc.contributor.authorSener, Alper
dc.contributor.authorBulut, Cemal
dc.contributor.authorTekin, Recep
dc.contributor.authorKahraman, Hasip
dc.contributor.authorOzgiray, Erkin
dc.contributor.authorYurtseven, Taskin
dc.contributor.authorSipahi, Hilal
dc.contributor.authorArda, Bilgin
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorTasbakan, Meltem
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorAydemir, Sohret
dc.contributor.authorUlusoy, Sercan
dc.date.accessioned2019-10-27T10:02:31Z
dc.date.available2019-10-27T10:02:31Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy. Patients and Methods: Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged > 18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016. Results: A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post therapy survival without any relapse or reinfection) decreased to 43%. Conclusion: We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multi drug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.en_US
dc.identifier.doi10.1016/j.clineuro.2018.06.008en_US
dc.identifier.endpage38en_US
dc.identifier.issn0303-8467
dc.identifier.issn1872-6968
dc.identifier.pmid29960893en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://doi.org/10.1016/j.clineuro.2018.06.008
dc.identifier.urihttps://hdl.handle.net/11454/30001
dc.identifier.volume172en_US
dc.identifier.wosWOS:000442980000006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofClinical Neurology and Neurosurgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcinetobacter baumanniien_US
dc.subjectMeningitisen_US
dc.subjectGlycylcyclineen_US
dc.subjectMultidrug resistant bacteriaen_US
dc.subjectCarbapenem-resistanten_US
dc.titleTigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu